Group 1 - GSK plc is recognized as one of the best performing pharmaceutical stocks in 2025, with Jefferies reaffirming a Buy rating and setting a price target of $55.60 [1] - The European Commission approved GSK's Shingrix vaccine in a prefilled syringe format, simplifying the administration process for healthcare professionals [2][3] - The new presentation of Shingrix is designed to improve protection against shingles without changing the indication or dosing, based on data confirming technical comparability with the existing vaccine [4] Group 2 - GSK, formerly known as GlaxoSmithKline, is a global biopharma company based in the UK, with a portfolio that includes over 20 vaccines and cancer treatments for various types of cancer [5]